ClinicalTrials.gg
CompletedNCT00646711Updated Mar 28, 2008

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

A Phase 2 interventional study of Depakote Delayed-Release/Depakote Sprinkle and Depakote ER in Pediatric Epilepsy, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2008-03-28.

Sponsored by Abbott · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Valproic Acid in Epilepsy — 2 open to participants now, 3 under way, 1 of them phase 3. Valproic Acid · Epilepsy.

Enrollment
16th of 23
16 · median 30
Started
2003
the only one that year
Phase 2
Only one
of the 23
Registered
7th of 23
by date
Lead sponsor
1 of 23
Abbott

Among the 23 studies testing Valproic Acid in Epilepsy, this one is the 16th largest by enrollment, is the only one that started in 2003, is the only one in phase 2, and was the 7th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 23 studies testing Valproic Acid in Epilepsy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Valproic Acid in Epilepsy, or all of them as a file.
02

Study summary

To assess the tolerability of switching from Depakote Sprinkle Capsules or Depakote tablets to Depakote ER tablets in the pediatric population.

03

Conditions studied

  • Pediatric Epilepsy

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient with a clinical diagnosis of epilepsy considered stable by the investigator.
  • Must be in good physical health, on the same dose of all medications, including Depakote and other AEDs, for 2 week period prior to randomization.
  • Minimum body weight of 37 lbs.

Exclusion criteria

Exclusion Criteria:

  • Six-month history of drug or alcohol abuse.
  • Status epilepticus within 6 months prior to screening.
  • Abnormal or /AST levels.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Sequence Group I

    Depakote Delayed Release/Depakote Sprinkle

    Drug: Depakote Delayed-Release/Depakote Sprinkle

  • Experimental
    Sequence Group II

    Depakote ER

    Drug: Depakote ER

Interventions

  • DrugDepakote Delayed-Release/Depakote Sprinkle

    Drug page: Valproic Acid

    Administered according to the subject's usual regimen.

    Also known as: ABT-711, Depakote DR, Depakote Sprinkle, divalproex sodium

  • Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.

    Also known as: ABT-711, Depakote Extended Release, divalproex sodium

06

What researchers measure

Primary outcomes

  1. Number of seizures

    Time frame: 2 weeks

  2. Number of Adverse Events

    Time frame: 2 weeks

07

Study locations

1 site
  • Richmond, Virginia 23284, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Dec 2003 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2008
First posted
Mar 28, 2008
Start
Feb 2003
Primary completionActual
Dec 2003
CompletionActual
Dec 2003
Last update
Mar 28, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00646711
Lead sponsor
Abbott
First posted
Mar 28, 2008
Start date
Feb 2003
Primary completion
Dec 2003
Completion
Dec 2003
Last update
Mar 28, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion